Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Impact of symptomatic MS therapy on pregnancy course and outcome
Multiple Sclerosis
P9 - Poster Session 9 (5:30 PM-6:30 PM)
12-011

Information on ST cessation behavior of pregnant MS women is lacking and data on the impact of ST pregnancy exposure on pregnancy outcome is still pending.  

To assess the course of symptomatic therapy (ST) intake in women with multiple sclerosis (MS) getting pregnant and to describe pregnancy outcomes.

Pregnancies after ST intake recorded in the German Multiple Sclerosis and Pregnancy Registry (DMSKW) between 2006 and 2020 are presented. Data was collected with a standardized questionnaire in regular telephone interviews during pregnancy and postpartum. Pregnancy outcomes were compared between women with ST pregnancy exposure (exposed group) and ST naïve pregnancies (control group).

Out of 2,449 registered pregnancies in the DMSKW, 1,396 (57.0%) ST naïve pregnancies (control group) were documented and 1,053 (43.0%) received ST anytime during the observational period. Out of 439 (17.9%) pregnancies with ST before conception, 282 (64.2%) continued ST during pregnancy (exposed group). Analgetics (31.3%), anticonvulsives (8.7%) and antidepressants (24.9%) were taken most frequently.

Spontaneous and elective abortions, ectopic pregnancies, still-, live-, and preterm births did not significantly differ between groups. 61 (3.9%) malformations were observed without a specific pattern (5 among fetal losses), 11(4.3%) in the exposed and 50 (3.9 %) in the control group (p-value: 0.739). Mean births weight (exposed: 3,207.5 g ± 584.6; controls: 3,273.0 g ± 585.5) and gestational week at births (exposed: 38.9 ± 2.2; controls: 39.1 ± 2.3) were nearly identical in both groups.  


 

Few women take ST prior to conceiving, but more than a half of this women continue ST during pregnancy. Pregnancy outcomes were similar between exposed and control group. However, the impact of ST stratified to different drug groups, has to be further investigated and will be presented at the time of the meeting.

Authors/Disclosures
Kerstin Hellwig (St. Josef Hospital Bochum)
PRESENTER
Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for INC research . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Merck . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer . The institution of Kerstin Hellwig has received research support from Roche . The institution of Kerstin Hellwig has received research support from Merck . The institution of Kerstin Hellwig has received research support from Biogen. The institution of Kerstin Hellwig has received research support from Genzyme . The institution of Kerstin Hellwig has received research support from Novartis . The institution of Kerstin Hellwig has received research support from TEVA.
Laura Witt, PhD (St. Josef Hospital, Ruhr University Bochum) Miss Witt has nothing to disclose.
Sandra Thiel (Department of Neurology, St. Josef Hospital, Ruhr University, Bochum, Germany) Ms. Thiel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer Healthcare .
Andrea Ines Ciplea (St. Josef Hospital Bochum) An immediate family member of Ms. Ciplea has received personal compensation for serving as an employee of Astra Zeneca. Ms. Ciplea has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Bayer Healthcare. Ms. Ciplea has received personal compensation in the range of $0-$499 for serving as a payment of travel-related expenses with Novartis. Ms. Ciplea has received personal compensation in the range of $0-$499 for serving as a payment of congress fees with Teva.
Ralf Gold, MD (Neurologische Universitaetsklinik) Dr. Gold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen . Dr. Gold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Gold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer Vital. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Pharamaceuticals. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Gold has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for SAGE Publishers. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Novartis. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Biogen. The institution of Dr. Gold has received research support from Novartis. The institution of Dr. Gold has received research support from Biogen.